Neratinib
About
Therapy type: Targeted therapy
Therapy strategy: HER2 inhibition
Mappings
NCI Thesaurus: Neratinib (ncit:C49094)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | HER2-positive | Invasive Breast Carcinoma | Neratinib | |
| FDA (1) | HER2-positive | Invasive Breast Carcinoma | Capecitabine, Neratinib | |
| EMA (1) HSE (1) | ER positive, HER2-positive, PR positive | Invasive Breast Carcinoma | Neratinib | |
| EMA (1) HSE (1) | ER positive, HER2-positive | Invasive Breast Carcinoma | Neratinib | |
| EMA (1) HSE (1) | HER2-positive, PR positive | Invasive Breast Carcinoma | Neratinib | |
| EMA (1) HSE (1) | ER positive, ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Neratinib | |
| EMA (1) HSE (1) | ER positive, ERBB2 amplification | Invasive Breast Carcinoma | Neratinib | |
| EMA (1) HSE (1) | ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Neratinib |